Open    Access



Construction of Alternatives for Stochastic Choice Models: Reflections FromChoice Experiments on Diabetic Markets



Author(s)

Christine C. Huttin

Full-Text PDF XML     71 Views

DOI:10.17265/2328-2185/2024.06.003

Aix Marseille University, Marseille, France
ENDEPUSresearch, Cambridge, USA
ENDEPLux Co, SARL S, Luxembourg

According to design theories, alternatives result from a construct; it can be from an analyst or decision makers and stakeholders. The generation of alternatives for the development of an economic model on medical markets was initiated with academic researchers, since medical and economic investigators also advised medical policies, especially at the time of the study on policy options to address shortages of critical drugs and to provide recommendations on controversial drugs in the TZD class.Global pharmaceutical pricing models have been so far driven by big life science companies in interaction withgovernments; the most common models discussed at a global level come from neo classical economic theory with adjustments of market prices, use of differentiated pricing to take into account adjustment of prices with GNPs differences or reference pricing to adjust access to consumers (e.g. in EU countries);other proposals include peak load pricing such as in Telecommunications. However, changes in international relation policies require now additional alternatives and objectives in a multi-stakeholder world for global health policies, the engagement of powerful non-state players, and the role of social medias into politics. In EWG-MCDA meeting at West Attica (Athens, 2024), it was proposed to use a C-K design framework to expand policy alternatives, using expansion of the concept space, especially for a cost sharing research agenda; after the recent communications at Euro and ADA conferences in July 2024, this paper proposes some advances for the general framework involving the South and North Hemispheres, and addressing common issues on major diseases such as diabetes.

global pharmaceuticals pricing, economic modelling, C-K design theory, policy analytics, cost sharing research